Potency of an inactivated influenza vaccine prepared from A/duck/Mongolia/119/2008 (H7N9) against the challenge with A/Anhui/1/2013 (H7N9)

Vaccine

Volumn 32, Issue 28, 2014, Pages 3473-3479

  Chu, Duc Huy ^a   Sakoda, Yoshihiro ^a   Nishi, Tatsuya ^a   Hiono, Takahiro ^a   Shichinohe, Shintaro ^a   Okamatsu, Masatoshi ^a   Kida, Hiroshi ^a,b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Antigenicity; H7N9 influenza; Human; Vaccine

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; VIRUS ANTIGEN; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA VIRUS; DRUG POTENCY; DUCK; IMMUNITY; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VIRUS A H7N9; MONGOLIA; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PHYLOGENY; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS PARTICLE; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CROSS REACTION; FEMALE; GENETICS; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; SERODIAGNOSIS;

ANIMALS; ANTIGENS, VIRAL; CROSS REACTIONS; FEMALE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; PHYLOGENY; RNA, VIRAL; VACCINES, INACTIVATED;

EID: 84901398021     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.060     Document Type: Article

References (30)

1. WHO Disease outbreak news. Human infection with influenza A(H7N9) virus in China - Update 2014, World Health Organization, [accessed 25.02.14]. http://www.who.int/csr/don/en/index.html.
2. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013, 368:1888-1897.
3. Kageyama T., Fujisaki S., Takashita E., Xu H., Yamada S., Uchida Y., et al. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 2013, 18:20453.
4. Watanabe T., Kiso M., Fukuyama S., Nakajima N., Imai M., Yamada S., et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013, 501:551-555.
5. Zhou J., Wang D., Gao R., Zhao B., Song J., Qi X., et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013, 499:500-503.
6. WHO Candidate vaccine viruses for avian influenza A(H7N9). Technical guidance - vaccine 2013, World Health Organization, [accessed 14.11.13]. http://www.who.int/influenza/vaccines/virus/candidates_reagents/a_h7n9/en/index.html.
7. Kida H., Sakoda Y. Library of influenza virus strains for vaccine and diagnostic use against highly pathogenic avian influenza and human pandemics. Dev Biol (Basel) 2006, 124:69-72.
8. Soda K., Sakoda Y., Isoda N., Kajihara M., Haraguchi Y., Shibuya H., et al. Development of vaccine strains of H5 and H7 influenza viruses. Jpn J Vet Res 2008, 55:93-98.
9. Isoda N., Sakoda Y., Kishida N., Soda K., Sakabe S., Sakamoto R., et al. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia. Arch Virol 2008, 153:1685-1692.
10. Itoh Y., Ozaki H., Tsuchiya H., Okamoto K., Torii R., Sakoda Y., et al. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 2008, 26:562-572.
11. Itoh Y., Ozaki H., Ishigaki H., Sakoda Y., Nagata T., Soda K., et al. Subcutaneous inoculation of a whole virus particle vaccine prepared from a non-pathogenic virus library induces protective immunity against H7N7 highly pathogenic avian influenza virus in cynomolgus macaques. Vaccine 2010, 28:780-789.
12. Nomura N., Sakoda Y., Soda K., Okamatsu M., Kida H. An H9N2 influenza virus vaccine prepared from a non-pathogenic isolate from a migratory duck confers protective immunity in mice against challenge with an H9N2 virus isolated from a girl in Hong Kong. J Vet Med Sci 2012, 74:441-447.
13. Okamatsu M., Sakoda Y., Hiono T., Yamamoto N., Kida H. Potency of a vaccine prepared from A/swine/Hokkaido/2/1981 (H1N1) against A/Narita/1/2009 (H1N1) pandemic influenza virus strain. Virol J 2013, 10:47.
14. Arikata M., Itoh Y., Okamatsu M., Maeda T., Shiina T., Tanaka K., et al. Memory immune responses against pandemic (H1N1) 2009 influenza virus induced by a whole particle vaccine in cynomolgus monkeys carrying Mafa-A1*052:02. PLoS ONE 2012, 7:e37220.
15. Sakoda Y., Sugar S., Batchluun D., Erdene-Ochir T.O., Okamatsu M., Isoda N., et al. Characterization of H5N1 highly pathogenic avian influenza virus strains isolated from migratory waterfowl in Mongolia on the way back from the southern Asia to their northern territory. Virology 2010, 406:88-94.
16. Hoffmann E., Stech J., Guan Y., Webster R.G., Perez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001, 146:2275-2289.
17. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987, 4:406-425.
18. OIE Manual of diagnostic test and vaccines for terrestrial animals 2013 2013, World Organization for Animal Health, [accessed 02.07.13]. http://www.oie.int/international-standard-setting/terrestrial-manual/access-online/.
19. Sakabe S., Sakoda Y., Haraguchi Y., Isoda N., Soda K., Takakuwa H., et al. A vaccine prepared from a non-pathogenic H7N7 virus isolated from natural reservoir conferred protective immunity against the challenge with lethal dose of highly pathogenic avian influenza virus in chickens. Vaccine 2008, 26:2127-2134.
20. Kida H., Yanagawa R. Isolation and characterization of influenza a viruses from wild free-flying ducks in Hokkaido, Japan. Zentralbl Bakteriol Orig A 1979, 244:135-143.
21. Ninomiya A., Imai M., Tashiro M., Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007, 25:3554-3560.
22. Belser J.A., Bridges C.B., Katz J.M., Tumpey T.M. Past, present, and possible future human infection with influenza virus A subtype H7. Emerg Infect Dis 2009, 15:859-865.
23. Update: influenza activity - United States and worldwide, 2003-04 season, and composition of the 2004-05 influenza vaccine. MMWR Morb Mortal Wkly Rep 2004, 53:547-552. Centers for Disease Control and Prevention (CDC).
24. Koopmans M., Wilbrink B., Conyn M., Natrop G., van der Nat H., Vennema H., et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004, 363:587-593.
25. Webster R.G., Geraci J., Petursson G., Skirnisson K. Conjunctivitis in human beings caused by influenza A virus of seals. N Engl J Med 1981, 304:911.
26. Kida H., Kawaoka Y., Naeve C.W., Webster R.G. Antigenic and genetic conservation of H3 influenza virus in wild ducks. Virology 1987, 159:109-119.
27. Smith G.E., Flyer D.C., Raghunandan R., Liu Y., Wei Z., Wu Y., et al. Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013, 31:4305-4313.
28. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21:1776-1779.
29. Osterholm M.T., Ballering K.S., Kelley N.S. Major challenges in providing an effective and timely pandemic vaccine for influenza A(H7N9). JAMA 2013, 309:2557-2558.
30. Kida H., Brown L.E., Webster R.G. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology 1982, 122:38-47.